24/10/2026 01:22
|
Medical, Health & Aged Care
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 months
TEVIMBRA-containing arm was...